Megval Injection

• If you have a known severe hypersensitivity or systemic allergic reaction to melphalan or any inactive ingredients in the product.
• In patients whose disease has demonstrated prior resistance to melphalan.

• Severe bone marrow suppression including low white blood cells, red blood cells, and platelets
• Gastrointestinal upset: nausea, vomiting, abdominal pain, and diarrhea
• Mouth sores and inflammation of the mouth (mucositis/stomatitis)
• Alopecia (hair loss)
• Fatigue, weakness, fever, and chills
• Changes in liver- or kidney-related blood tests

• Skin rash, itching, and skin pigmentation changes
• Changes in blood electrolyte levels
• Shortness of breath or cough
• Injection site pain or inflammation

• Severe bone marrow suppression: fever, chills, signs of infection, unusual bleeding, or severe weakness.
• Severe allergic reaction: sudden difficulty breathing, swelling of the face or throat, rash, low blood pressure, or collapse during or shortly after administration.
• Lung problems: new or worsening cough, shortness of breath, or breathing difficulty.
• Severe Mucositis: painful mouth sores that make it difficult to eat or drink
• Secondary blood cancers: long-term exposure to melphalan may be associated with an increased risk of secondary blood cancers such as acute myeloid leukaemia (AML) or myelodysplastic syndromes (MDS).

• Megval injection must be administered exclusively by qualified medical personnel in a specialized clinical setting.
• It is administered as an intravenous infusion over a specified duration according to the conditioning or chemotherapy protocol.
• Do not self-administer this medication.

• Store unmixed vials as directed on the product packaging.
• The reconstituted and diluted solution degrades rapidly and must be administered within strict timelines.
• Healthcare professionals prepare, handle, and dispose of the product in accordance with standard hazardous cytotoxic handling guidelines.

• Keep up with your scheduled blood tests and medical appointments.
• Report fever, chills, unusual bleeding, or signs of infection promptly.
• Maintain good oral hygiene and inform your healthcare team about painful mouth sores.
• During certain high-dose treatment protocols, your oncology team may recommend oral cryotherapy (ice chips) to help reduce mucositis.
• Inform your doctor if you wish to discuss fertility preservation before treatment.

Overdose

Missed a Dose

Interactions with other medicines

• Tell your doctor about all medicines, vitamins, supplements, and herbal products you take.
• Cyclosporine: high-dose IV melphalan used with cyclosporine may increase the risk of kidney impairment.
• Live vaccines: generally avoid live vaccines in patients with a weakened immune system.
• Other medicines that suppress the bone marrow or increase infection risk may increase treatment-related toxicity.

Interactions with food items